Blockade of calcitonin gene-related peptide release after superior sagittal sinus stimulation in cat: a comparison of avitriptan and CP122,288

@article{Knight1999BlockadeOC,
  title={Blockade of calcitonin gene-related peptide release after superior sagittal sinus stimulation in cat: a comparison of avitriptan and CP122,288},
  author={Yolande E. Knight and Lars Edvinsson and Peter J. Goadsby},
  journal={Neuropeptides},
  year={1999},
  volume={33},
  pages={41-46}
}
The pathophysiological basis for the pain of migraine has been the subject of substantial attention and must include activation of elements of the trigeminal innervation of the cranial vessels, the trigeminovascular system. Recently, consideration of trigeminal-evoked neurogenic plasma protein extravasation (PPE) as a model for the pain has driven the search for compounds with specific anti-extravasation properties. Calcitonin gene-related peptide (CGRP) is a marker for trigeminovascular… Expand
4991W93 inhibits release of calcitonin gene-related peptide in the cat but only at doses with 5HT1B/1D receptor agonist activity?
TLDR
Given that 4991W93 is inactive clinically at non-vascular doses, it seems clear that the 5HT(1B/1D) agonist effects of the compound are necessary for blockade of CGRP release and thus any anti-migraine action. Expand
Calcitonin Gene-Related Peptide Antagonists as Treatments of Migraine and Other Primary Headaches
TLDR
The prospect of a non-vasoconstricting therapy for acute migraine offers a real opportunity to patients, and perhaps more importantly, provides a therapeutic rationale to reinforce migraine as a neurological disorder. Expand
CGRP antagonists: hope for a new era in acute migraine treatment.
TLDR
The rationale for the use of CGRP-receptor antagonists is reviewed, current developments and future perspectives are outlined, and the therapeutic approach may offer advantages over the current mainstay of specific acute migraine treatment with 5-HT1B/1D receptor agonists (triptans). Expand
Calcitonin Gene‐Related Peptide Modulators – The History and Renaissance of a New Migraine Drug Class
TLDR
Data indicated that the therapeutic site of action of the CGRP‐RAs was peripheral not central; that IV C GRP had most likely evoked migraine through an action at sites outside the blood‐brain barrier; and that migraine pain was therefore, at least in part, peripheral in origin. Expand
Calcitonin Gene-Related Peptide-Targeted Therapies for Migraine and Cluster Headache: A Review
TLDR
A growing body of clinical trials studying CGRP-targeted therapies for migraine and cluster headache is discussed, including two monoclonal antibodies in clinical trials for cluster headache prevention and several other small-molecular C GRP receptor antagonists in earlier stages of development. Expand
Serotonin 5-HT1B/1D Receptor Agonists in Migraine
TLDR
Some aspects of the pharmacokinetics of the various triptans, such as the relationship between time to reach peak plasma concentrations and half-lives and clinical efficacy, may reveal information about the fundamental processes at work in acute migraine. Expand
Clinical and Preclinical Rationale for CGRP‐Receptor Antagonists in the Treatment of Migraine
TLDR
Both intravenous olcegepant and oral telcagepant have been effective, safe, and well tolerated in phase I and II studies and are currently in phase III trials, and preliminary results are favorable. Expand
4991W93, a potent blocker of neurogenic plasma protein extravasation, inhibits trigeminal neurons at 5-hydroxytryptamine (5-HT1B/1D) agonist doses
TLDR
Data suggest that 4991W93 is only effective at modulating the trigeminocervical complex at 5-HT(1B/1D) agonist doses, to account for neurogenic dural plasma protein extravasation blockade in animal studies. Expand
CGRP and its receptors provide new insights into migraine pathophysiology
TLDR
This Review considers the evidence pointing towards a neuronal mechanism in migraine development, highlighting the role of calcitonin gene-related peptide (CGRP), which is found in small to medium-sized neurons in the trigeminal ganglion, and examines whether other drugs, such as triptans, might exert their antimigraine effects via their actions on the neuronal circuit as opposed to the intracranial vasculature. Expand
New targets in the acute treatment of headache
  • P. Goadsby
  • Medicine
  • Current opinion in neurology
  • 2005
TLDR
The prospect of a non-vasoconstrictor acute migraine therapy offers a real opportunity to patients, and perhaps more importantly, provides a therapeutic rationale to plant migraine and cluster headache firmly in the brain as neurological problems. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 37 REFERENCES
Effect of a serotonin agonist (sumatriptan) on the peptidergic innervation of the rat cerebral dura mater and on the expression of c‐fos in the caudal trigeminal nucleus in an experimental migraine model
The supratentorial cerebral dura of the albino rat is equipped with a rich sensory innervation including nociceptive axons and their terminals, which display intense calcitonin gene‐related peptideExpand
Vasoactive peptide release in the extracerebral circulation of humans during migraine headache
TLDR
A substantial elevation of the calcitonin gene‐related peptide level in the external jugular but not the cubital fossa blood was seen in both classic and common migraine, and may have importance in the pathophysiology of migraine. Expand
Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion
TLDR
Drug-induced attenuation of levels of CGRP in plasma may reflect inhibition of release, to provide evidence to explain blockade of neurogenic extravasation of plasma. Expand
Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system
TLDR
The observation of elevation of substance P—like and CGRP‐like immunoreactivity after activation of the nociceptive afferent system of the head provides new insights into a putative role of peptides in the pathophysiology of migraine and cluster headache, and suggests new areas of possible therapeutic intervention. Expand
Neuropeptides in Migraine and Cluster Headache
TLDR
Treatment with sumatriptan aborts headache in migraine and cluster headache as well as the concomitant peptide release and subjects with spontaneous attacks of migraine show release of CGRP in parallel with headache. Expand
Differential Distribution of 5Ht1D-and 5HT1B-Immunoreactivity within the Human Trigemino-Cerebrovascular System: Implications for the Discovery of New Antimigraine Drugs
TLDR
A differential distribution of these receptor subtypes within the human trigemino-cerebrovascular system is demonstrated using 5HT1D- and5HT1B-receptor-specific antibodies and has important implications for the design of new antimigraine drugs. Expand
The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats
TLDR
These data characterize some aspects of the cerebrovascular physiology of the trigeminovascular system and demonstrate important interactions between this system and the effective antimigraine agents sumatriptan and dihydroergotamine and that such interactions can be represented in animal models. Expand
Calcitonin gene-related peptide: functional role in cerebrovascular regulation.
TLDR
The cerebrovascular trigeminal neuronal system, in which CGRP is the most potent vasoactive constituent, may participate in a reflex or local response to excessive cerebral vasoconstriction that restores normal vascular diameter. Expand
Calcitonin Gene-Related Peptide is Released from Capsaicin-Sensitive Nerve Fibres and Induces Vasodilatation of Human Cerebral Arteries Concomitant with Activation of Adenylyl Cyclase
TLDR
The results suggest that CGRP-1 receptors coupled to adenylyl cyclase are present in human cerebral arteries and are associated with vasomotor effects of calcilonin gene-related peptide analogues at neurosurgical operations. Expand
Depletion of calcitonin gene-related peptide from the caudal trigeminal nucleus of the rat after electrical stimulation of the Gasserian ganglion
TLDR
Electrical stimulation of the Gasserian ganglion resulted in partial depletion of calcitonin gene-related peptide (CGRP) from ipsilateral central terminals of pseudounipolar primary sensory ganglions cells, which might be of importance in the pathogenesis of migraine headache. Expand
...
1
2
3
4
...